Charles Schwab’s Charles River Laboratories CRL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$106M Sell
467,663
-1,304
-0.3% -$232K 0.01% 761
2026
Q1
$80.9M Buy
468,967
+14,814
+3% +$2.75M 0.01% 848
2025
Q4
$90.6M Sell
454,153
-21,889
-5% -$3.97M 0.01% 778
2025
Q3
$74.5M Sell
476,042
-69,707
-13% -$11.1M 0.01% 886
2025
Q2
$82.8M Sell
545,749
-31,573
-5% -$4.21M 0.01% 767
2025
Q1
$86.9M Buy
577,322
+24,347
+4% +$4.08M 0.02% 721
2024
Q4
$102M Buy
552,975
+37,753
+7% +$7.27M 0.02% 661
2024
Q3
$101M Buy
515,222
+32,311
+7% +$6.71M 0.02% 643
2024
Q2
$99.8M Buy
482,911
+34,102
+8% +$7.73M 0.02% 654
2024
Q1
$122M Sell
448,809
-64,418
-13% -$15.4M 0.03% 522
2023
Q4
$121M Buy
513,227
+21,028
+4% +$4.14M 0.03% 474
2023
Q3
$96.5M Buy
492,199
+11,053
+2% +$2.27M 0.03% 515
2023
Q2
$101M Buy
481,146
+7,177
+2% +$1.43M 0.03% 511
2023
Q1
$95.7M Buy
473,969
+10,364
+2% +$2.35M 0.03% 520
2022
Q4
$101M Buy
463,605
+22,438
+5% +$4.9M 0.03% 478
2022
Q3
$86.8M Buy
441,167
+134,509
+44% +$29M 0.03% 488
2022
Q2
$65.6M Buy
306,658
+18,733
+7% +$4.58M 0.02% 616
2022
Q1
$81.8M Buy
287,925
+13,865
+5% +$4.28M 0.02% 597
2021
Q4
$103M Sell
274,060
-316
-0.1% -$123K 0.03% 517
2021
Q3
$113M Sell
274,376
-103,186
-27% -$42.9M 0.04% 440
2021
Q2
$140M Buy
377,562
+94,810
+34% +$31.7M 0.05% 370
2021
Q1
$82M Sell
282,752
-14,976
-5% -$4.16M 0.03% 563
2020
Q4
$74.4M Sell
297,728
-3,164
-1% -$754K 0.03% 554
2020
Q3
$68.1M Sell
300,892
-113,749
-27% -$23.6M 0.03% 488
2020
Q2
$72.3M Sell
414,641
-5,077
-1% -$810K 0.04% 468
2020
Q1
$53M Buy
419,718
+22,020
+6% +$3.3M 0.03% 503
2019
Q4
$60.8M Buy
397,698
+7,933
+2% +$1.1M 0.03% 522
2019
Q3
$51.6M Buy
389,765
+30,884
+9% +$4.14M 0.03% 560
2019
Q2
$50.9M Sell
358,881
-101,910
-22% -$13.8M 0.03% 555
2019
Q1
$66.9M Buy
460,791
+67,125
+17% +$8.82M 0.04% 408
2018
Q4
$44.6M Sell
393,666
-4,217
-1% -$528K 0.03% 501
2018
Q3
$53.5M Buy
397,883
+15,301
+4% +$1.89M 0.04% 499
2018
Q2
$42.9M Buy
382,582
+80,519
+27% +$8.7M 0.03% 565
2018
Q1
$32.2M Buy
302,063
+12,670
+4% +$1.37M 0.03% 695
2017
Q4
$31.7M Buy
289,393
+6,628
+2% +$721K 0.03% 665
2017
Q3
$30.5M Buy
282,765
+15,562
+6% +$1.6M 0.03% 633
2017
Q2
$27M Buy
267,203
+4,865
+2% +$448K 0.03% 649
2017
Q1
$23.6M Buy
262,338
+19,716
+8% +$1.67M 0.02% 723
2016
Q4
$18.5M Sell
242,622
-156,186
-39% -$11.9M 0.02% 801
2016
Q3
$33.2M Sell
398,808
-39,080
-9% -$3.28M 0.04% 473
2016
Q2
$36.2M Sell
437,888
-51,970
-11% -$4.28M 0.05% 406
2016
Q1
$37.2M Sell
489,858
-50,704
-9% -$3.75M 0.05% 374
2015
Q4
$43.5M Sell
540,562
-58,221
-10% -$4.2M 0.06% 314
2015
Q3
$38.1M Buy
598,783
+31,065
+5% +$2.23M 0.06% 326
2015
Q2
$39.9M Buy
567,718
+160,154
+39% +$11.9M 0.06% 337
2015
Q1
$32.3M Buy
407,564
+276,502
+211% +$20.4M 0.05% 403
2014
Q4
$8.34M Sell
131,062
-27,419
-17% -$1.72M 0.01% 1025
2014
Q3
$9.47M Sell
158,481
-36,735
-19% -$2.1M 0.02% 873
2014
Q2
$10.4M Sell
195,216
-938
-0.5% -$51.5K 0.02% 800
2014
Q1
$11.8M Buy
196,154
+75,882
+63% +$4.42M 0.02% 685
2013
Q4
$6.38M Sell
120,272
-87,900
-42% -$4.41M 0.01% 1065
2013
Q3
$9.69M Sell
208,172
-70,852
-25% -$3.25M 0.02% 662
2013
Q2
$11.6M Buy
+279,024
New +$12M 0.03% 517

Other funds holding CRL

Charles Schwab's CRL Position: Q2 2026 in Review

Charles Schwab reduced its Charles River Laboratories (CRL) stake by 0.28% in Q2 2026, selling an estimated $232K and leaving 467,663 shares worth $106M. The position accounts for 0.01% of the portfolio, ranked #761.

Charles Schwab first reported a position in CRL in Q2 2013 and has held it in 53 quarters since. The position peaked at $140M in Q2 2021. 565 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

  • Charles Schwab held 467,663 shares of Charles River Laboratories worth $106M as of Q2 2026.
  • Charles Schwab sold 1,304 Charles River Laboratories shares in Q2 2026, an estimated $232K.
  • Charles River Laboratories made up 0.01% of Charles Schwab's portfolio in Q2 2026, its #761 holding.
  • Charles Schwab first reported a position in Charles River Laboratories in Q2 2013 and has held it in 53 quarters since.
  • Charles Schwab's Charles River Laboratories position peaked at $140M in Q2 2021.
  • 565 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.